Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 4.5 microgram/ml (equivalent: adrenaline (epinephrine), qty 2.5 microgram/ml); bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: sodium metabisulfite; hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia; epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia; continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - united kingdom: methotrexate injection is an anti-metabolite medicine and immunosuppressant. it is used in large doses to treat certain types of cancer such as breast cancer. in smaller doses it can be used to treat severe psoriasis, when it has not responded to other treatments. ireland: methotrexate is used to treat cancer, such as: lymphatic leukemia (disease of the blood or bone marrow), breast cancer, bone cancer, head and neck cancer, gynaecologic cancer (choriocarcinoma, trophoblastic disease ? tumor development directly associated with pregnancy), and non-hodgkin?s lymphoma. methotrexate can also be used to treat severe psoriasis, when it has not responded to other treatments.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml); adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; sodium metabisulfite; water for injections; hydrochloric acid - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia; epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia; continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; dilute hydrochloric acid - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; dilute hydrochloric acid; sodium chloride - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 52.7 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

Malta - englanti - Medicines Authority

octapharma (ip) limited - immunoglobulin g, human - solution for injection - immunoglobulin g, human 165 mg/ml - immune sera and immunoglobulins

Malta - englanti - Medicines Authority

octapharma (ip) limited - immunoglobulin g, human - solution for infusion - immunoglobulin g, human 100 mg i/ml - immune sera and immunoglobulins

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.